Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A long-acting somatostatin analog FDA-approved for acromegaly and gastroenteropancreatic neuroendocrine tumors. Administered as a deep subcutaneous depot injection once monthly.
A synthetic analog of growth hormone-releasing hormone (GHRH) that is FDA-approved for HIV-associated lipodystrophy. One of the few peptides with a clear FDA-approved indication, making it a useful reference point for the broader GHRH analog class.
Binds primarily to somatostatin receptor subtypes 2 and 5 (SSTR2, SSTR5), inhibiting growth hormone secretion, reducing IGF-1 levels, and suppressing tumor growth in neuroendocrine tumors.
Binds to GHRH receptors on the pituitary gland, stimulating pulsatile GH release. Reduces visceral adipose tissue (VAT) through GH-mediated lipolysis. Maintains the natural pulsatile pattern of GH secretion, preserving feedback mechanisms.
- Acromegaly
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- Carcinoid syndrome
- HIV-associated lipodystrophy (FDA-approved)
- Visceral fat reduction
- Metabolic health improvement
- Growth hormone optimization (off-label)
- Cognitive function (emerging research in older adults)
- GI side effects (diarrhea, abdominal pain)
- Gallstones
- Injection site reactions
- Hyperglycemia
- Bradycardia
- Injection site reactions (common)
- Fluid retention and edema
- Arthralgia (joint pain)
- Potential glucose metabolism effects
- Contraindicated in active malignancy
FDA-approved as Somatuline Depot (2007) for acromegaly and GEP-NETs. Administered as a deep subcutaneous injection in the gluteal region once every 4 weeks.
FDA-approved as Egrifta (tesamorelin for injection) in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Also available through compounding pharmacies for off-label use with a physician prescription.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.